Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300
Debt
Debt-to-Equity Ratio-13.08
Current Ratio1.82
Quick Ratio1.49
Price-To-Earnings
Trailing P/E Ratio-2.41
Forward P/E Ratio-4.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.02 million
Price / Sales7.48
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book23.89
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-211.13%
Return on Equity-586.25%
Return on Assets-58.31%
Miscellaneous
Employees138
Outstanding Shares29,000,000
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics Inc (NASDAQ:NEOS) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.02. The firm earned $10.73 million during the quarter. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 211.13%. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
5 equities research analysts have issued 12 month target prices for Neos Therapeutics' stock. Their predictions range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' share price to reach $15.3333 in the next year. View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis 1) On 01/10/18 NEOS announced that study findings for two of its ADHD medications, ER, were presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on 02/20/18 PDL Biopharma (Not Covered) announced termination of interest in acquiring 02/26/18 NEOS announced the U.S. launch of Adzenys ER, making it NEOS’s third ADHD product launch in less than two years; 4) as discussed at the company’s analyst day in March of 2018, NEOS plans to advance its drug candidate for the treatment of nausea and vomiting into the clinic in 2H18 and to identify one additional branded product candidate in CNS or gastroenterology in 2018; and 5) as of 03/31/18 the company held $37.2MM in cash and cash equivalents." (5/9/2018)
- 2. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (3/22/2018)
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), CannTrust (CNTTF), Odonate Therapeutics (ODT), Adamas Pharmaceuticals (ADMS), Geron (GERN), GlycoMimetics (GLYC), Dicerna Pharmaceuticals (DRNA), Aduro BioTech (ADRO), Progenics Pharmaceuticals (PGNX), Akebia Therapeutics (AKBA), Keryx Biopharmaceuticals (KERX), Kura Oncology (KURA), Viking Therapeutics (VKTX) and Aclaris Therapeutics (ACRS).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Dr. Vipin K. Garg, CEO, Pres & Director (Age 60)
- Mr. Richard I. Eisenstadt, Chief Financial Officer (Age 60)
- Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
- Mr. Russ McMahen, VP of R&D
- Dr. Carolyn R. Sikes Ph.D., VP of Clinical Affairs
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
Has Neos Therapeutics been receiving favorable news coverage?
News articles about NEOS stock have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Neos Therapeutics earned a daily sentiment score of 0.23 on Accern's scale. They also gave headlines about the company an impact score of 46.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Neos Therapeutics' major shareholders?
Neos Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (7.93%), BlackRock Inc. (6.33%), Lyon Street Capital LLC (5.02%), Russell Investments Group Ltd. (2.86%), Cortina Asset Management LLC (2.13%) and Sphera Funds Management LTD. (1.11%). Company insiders that own Neos Therapeutics stock include Bryant Fong and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.
Which major investors are selling Neos Therapeutics stock?
Which major investors are buying Neos Therapeutics stock?
NEOS stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Russell Investments Group Ltd., Sphera Funds Management LTD., Millennium Management LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Quantitative Systematic Strategies LLC and OMERS ADMINISTRATION Corp. Company insiders that have bought Neos Therapeutics stock in the last two years include Bryant Fong and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $6.45.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $187.03 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
